CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to CELG-RI

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
9mo
CELG-RIPDUFA
Phase 3

FDA PDUFA Date mezigdomide

Mezigdomide
May 13STALE
Source
00%
Competitive Landscape

1 competitor in Relapsed or Refractory Multiple Myeloma

View Full Landscape
Drug Information

Target Indication

Relapsed or Refractory Multiple Myeloma

Clinical Trial

NCT05552976

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.